
Kenya moves closer to ending its Ebola outbreak as recovered patients go home, while British farms record their first cases of the Shamonda virus. Two preliminary heart studies examine energy drinks and cannabis, and a trial in Rwanda tests a long-acting injection designed to prevent malaria for several months.
Kenya discharges five Ebola patients and releases 46 more contacts from quarantine
Kenya’s Ministry of Health said five male patients treated for Ebola caused by the Bundibugyo virus had been discharged after completing treatment and testing negative, two from Kenyatta National Hospital and three from Nairobi Hospital. Another 46 contacts who completed monitoring in good health have left quarantine, after twenty others went home on 25 October. The remaining 52 contacts are expected to be released by 11 November, once 21 days have passed since their last exposure.
Health Director General Patrick Amoth said confirmed cases remained at nine, with two deaths, and that no new case had been recorded since 19 October. All cases belong to one cluster linked to the first imported case, with no community spread. Two patients are still in hospital. Once the last patient recovers or dies, a 42-day countdown will begin before the outbreak can be declared over. The ministry said Kenya remained open, despite travel measures announced by Saudi Arabia and Kuwait.
The Bundibugyo virus, named after the Ugandan district where it was first identified, is one of the species that cause Ebola disease, a form of haemorrhagic fever. It caused outbreaks in 2007 and 2012 before the current epidemic, which began in the Democratic Republic of Congo and is the fastest-growing Ebola outbreak on record. There is no approved vaccine or treatment for this species. Kenya recorded its first case after the disease was imported, and later confirmed infections among health workers.
Shamonda virus is found in British livestock for the first time
Shamonda virus has been detected for the first time in British livestock, at dairy farms in Powys in Wales and Shropshire in England, the UK Health Security Agency has confirmed. The virus is thought to spread mainly through bites from Culicoides midges and chiefly affects cattle. Fourteen countries in western Europe have recorded cases, including farms in Jersey and the Republic of Ireland. Keepers have been told to watch for fever, diarrhoea, lethargy and reduced milk yields.
The agency said there was no evidence of wider transmission among people and that the risk to the general public was very low. Only one human infection has been recorded, in a severely immunocompromised patient in Lyon, France, last month, which French officials called an exceptional case. The health board said no extra disease-control measures were needed, and the Food Standards Agency said there was no evidence that the virus posed a risk to food safety.
Shamonda virus belongs to a group of midge-borne viruses closely related to the Schmallenberg and Akabane viruses, which infect cattle, sheep, goats and alpacas. It was first isolated in Nigeria in 1965 and has since appeared sporadically in Africa and Japan. A new European variant was identified in July after investigations on cattle farms in Germany and Switzerland and then spread to France, Spain, Portugal and other countries. The Lyon patient died after a likely midge bite in eastern France.
Energy drinks and stimulant supplements feature more often in reports of cardiac arrest, study finds
Caffeinated energy drinks and stimulant supplements appeared disproportionately often in reports of serious heart events to the US Food and Drug Administration, according to preliminary research to be presented at the American Heart Association’s Scientific Sessions in Chicago. Researchers reviewed 28,345 adverse-event reports from 2017 to 2025. Cardiac arrest was reported about 11 times more often with caffeine and stimulant products than with other foods and supplements, and heart attacks about 4.5 times more often.
About 45% of the reports linking these products to heart events involved adults aged 18 to 34, a group not usually considered at high risk. Study author Sai Samayamanthula, a medical student at the University of Virginia, said regular users could quickly exceed the recommended daily caffeine limit. Gregory Marcus of the University of California, San Francisco, who was not involved, said the work raised concerns but did not prove that the products caused the events. The abstract has not been peer reviewed.
Energy drinks are non-alcoholic beverages containing stimulants, usually caffeine at higher levels than ordinary soft drinks, and often taurine, marketed to reduce tiredness. The heart association says up to 400mg of caffeine a day is generally safe for most adults, while some energy drinks hold three times as much caffeine per ounce as brewed coffee. In the United States they are regulated as foods or dietary supplements, so they do not undergo the safety testing required for medicines.
Rwanda hosts Africa’s first early-stage trial of a long-acting malaria injection
Medicines for Malaria Venture and the Rwandan research organisation Rinda Ubuzima have launched a Phase 1b trial of MMV371, a long-acting injectable intended to prevent malaria. It is the first Phase 1 trial of such an injection to take place in Africa. The study will assess the safety and tolerability of the compound in Rwandan adults and adolescents, explore how well it works and measure how the body absorbs and processes it.
Earlier research in the United Kingdom found MMV371 was well tolerated in healthy adults and could offer protection for about three months. Martin Fitchet, chief executive of the venture, said such injections could change how prevention is delivered by giving lasting protection from a single dose. Marie Michele Umulisa, who heads Rinda Ubuzima, said the study showed African researchers could be active contributors to developing solutions for the communities that need them.
According to the World Health Organization, malaria caused more than 280 million cases and 600,000 deaths in 2024, 95 per cent of them in Africa. Drug resistance and shifting patterns of disease linked to extreme weather have increased the need for new tools. Medicines for Malaria Venture is a not-for-profit public-private partnership set up as a foundation in Switzerland in 1999, with funding from governments, the World Bank and the Rockefeller Foundation, to develop antimalarial drugs.
Cannabis use is linked to higher odds of stroke in a survey of US adults
Cannabis use was associated with higher odds of cardiovascular disease, especially stroke, in an analysis of almost half a million American adults, according to preliminary research to be presented at the American Heart Association’s Scientific Sessions. Researchers used telephone survey data from 2020 to 2024. People who used cannabis on one to five days a month had 23% higher odds of reporting heart disease or stroke than non-users, and heavy users had 21% higher odds.
The strongest link was with stroke: low-frequency use was associated with 40% higher odds and heavy use with 25% higher odds, while no significant link was found with heart attack. The pattern held whether cannabis was smoked or eaten. Study author Aabha Divya of Tulane University said the team had expected the risk to rise steadily with use but found it was not so, and urged doctors to ask about cannabis as they do about tobacco and alcohol.
Divya said one in six US adults reported using cannabis in the previous month in 2024, up from one in ten in 2020. The plant contains more than a hundred cannabinoids, chief among them tetrahydrocannabinol, or THC, which produces its psychoactive effects. Earlier studies had raised concerns about the heart but with inconsistent results, and the findings remain preliminary until they are published in a peer-reviewed journal. In the United States, federal restrictions limit medical research on cannabis.